CN112998101A - Solid beverage of inhibitor of KAT7 gene for human body aging and preparation method thereof - Google Patents
Solid beverage of inhibitor of KAT7 gene for human body aging and preparation method thereof Download PDFInfo
- Publication number
- CN112998101A CN112998101A CN202110423994.8A CN202110423994A CN112998101A CN 112998101 A CN112998101 A CN 112998101A CN 202110423994 A CN202110423994 A CN 202110423994A CN 112998101 A CN112998101 A CN 112998101A
- Authority
- CN
- China
- Prior art keywords
- kat7
- gene
- parts
- inhibitor
- solid beverage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/30—Further treatment of dried tea extract; Preparations produced thereby, e.g. instant tea
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The application relates to the technical field of solid beverages, and particularly discloses a human body aging KAT7 gene inhibitor solid beverage and a preparation method thereof. The technical key points are as follows: a solid beverage of an inhibitor of a human body senescence KAT7 gene comprises 35-45 wt% of the human body senescence KAT7 gene inhibitor, wherein the human body senescence KAT7 gene inhibitor is a mixture consisting of yeast extract, green tea extract and grape skin extract freeze-dried powder, and the weight ratio of the yeast extract, the green tea extract and the grape skin extract freeze-dried powder is 1 (3-5) to (2-4). The preparation method of the solid beverage comprises the following steps: (1) sieving; (2) weighing; (3) premixing; (4) mixing; (5) subpackaging and filling; (6) and (6) packaging and warehousing. By adding the KAT7 gene inhibitor into the solid beverage, the normal expression of the KAT7 gene can be inhibited after the solid beverage is absorbed by a human body, so that the effects of aging resistance and oxidation resistance are achieved.
Description
Technical Field
The application relates to the technical field of solid beverages, in particular to a solid beverage of an inhibitor of human body aging KAT7 gene and a preparation method thereof.
Background
Aging is an inevitable process currently used by everyone, and almost all organisms suffer from functional decline. Cellular senescence is a state of permanent growth arrest and has become a hallmark of senescence and a fundamental driver of the senescence process. Over time, aging cells accumulate in tissues, causing the body to age, and causing diseases associated with aging, such as hepatic steatosis, osteoarthritis, and the like.
Senescent cells play a causative role in aging in the body, for example, senescent cells accumulate gradually in degenerated liver, and the elimination of senescent cells in the liver can alleviate the development of hepatic steatosis, i.e., delay or reverse cellular senescence may provide a new prophylactic approach for preventing senescence-associated disorders. Relevant researches show that lysine acetyltransferase (KAT 7), a histone acetyltransferase, is listed as a preferred anti-aging gene in a model of premature senility hMPC, the inactivation of KAT7 can reduce the acetylation of histone H3 lysine 14, inhibit the transcription of p15INK4b, relieve the aging of hMPC and reduce the accumulation of aging cells in tissues, so that the activity of KAT7 gene is inhibited, the gene is inactivated and the anti-aging capability of organisms can be endowed to a greater extent.
In view of the above-mentioned related technologies, the inventors of the present invention have not found any relevant documents or patents in which KAT7 gene inhibitors are used in solid beverages to impart anti-aging function thereto. Therefore, a new solution is needed to solve the above problems.
Disclosure of Invention
In order to endow the solid beverage with anti-aging and anti-oxidation effects, the application provides the solid beverage of the inhibitor of the human body aging KAT7 gene and a preparation method thereof.
In a first aspect, the application provides a solid beverage of an inhibitor of human body aging KAT7 gene, which adopts the following technical scheme:
a solid beverage of an inhibitor of a human body senescence KAT7 gene comprises 35-45 wt% of the human body senescence KAT7 gene inhibitor, wherein the human body senescence KAT7 gene inhibitor is a mixture consisting of yeast extract, green tea extract and grape skin extract freeze-dried powder, and the weight ratio of the yeast extract, the green tea extract and the grape skin extract freeze-dried powder is 1 (3-5) to (2-4).
By adopting the technical scheme, the yeast extract is a product obtained by completely autolyzing yeast after plasmolysis by using a self-hydrolytic enzyme system after plasmolysis, and removing cell walls and insoluble molecules, and the main components of the yeast extract are natural active substances such as micromolecule nucleotide, polypeptide, vitamin and the like, so that the normal expression of KAT7 gene can be influenced, and the anti-aging effect is achieved. The green tea extract is an active component extracted from green tea leaves, mainly comprises EGCG (epigallocatechin gallate), is a main component of green tea polyphenol, has the effects of resisting bacteria, viruses, oxidation, arteriosclerosis, tumors and the like, and also has the effects of resisting free radical DNA damage, interfering signal transmission required by cancer cell survival and inhibiting normal expression of KAT7 gene, so that the green tea extract has a certain anti-aging effect. The resveratrol is a non-flavonoid polyphenol organic compound, has the effects of resisting oxidation, inflammation and cancer, protecting cardiovascular and the like, and researches show that the resveratrol can be used as an activator of a stronger silent information factor, participates in the regulation and control of the average life cycle of organic organisms, and can cause physiological changes of delaying aging and prolonging the service life. The three components are compounded and used, and the solid beverage can be added into the solid beverage to endow the solid beverage with the effects of aging resistance, oxidation resistance and the like.
More preferably, the weight ratio of the yeast extract to the green tea extract to the grape skin extract freeze-dried powder is 1:4: 3.
By adopting the technical scheme, the weight ratio of the yeast extract to the green tea extract to the grape skin extract freeze-dried powder is controlled to be 1:4:3, the yeast extract to the green tea extract to the grape skin extract freeze-dried powder is the optimal ratio, and the yeast extract, the green tea extract and the grape skin extract freeze-dried powder can fully play anti-aging and anti-oxidation effects when added into the solid beverage, so that the solid beverage has higher nutritional value.
More preferably, the yeast extract is a pichia pastoris extract.
By adopting the technical scheme, compared with the common yeast extract, the pichia pastoris extract has high content of active substances such as small molecular nucleotides, polypeptides and the like and high activity, and can obviously inhibit the expression of KAT7 gene to inactivate the KAT7 gene, so that the inhibition performance is good.
Further preferably, the solid beverage comprises the following components in parts by weight: 350 parts of human body senescence KAT7 gene inhibitor 210-containing material, 10-30 parts of bovine colostrum, 15-25 parts of L-lysine hydrochloride, 40-60 parts of L-glutamine, 150 parts of magnesium malate 100-containing material, 0.5-1.5 parts of vitamin C, 200 parts of calcium citrate-containing material, 10-50 parts of trehalose, 0.01-0.02 part of edible essence and 0.01-0.05 part of stevioside.
By adopting the technical scheme, the main nutrition physiological action of the L-lysine hydrochloride is to participate in the biosynthesis of protein as a substrate, and the protein metabolism can be regulated and controlled through various ways: protein metabolism is indirectly influenced by regulating endocrine hormones such as growth hormone, insulin and insulin-like growth factor; lysine is used as a signal molecule to directly regulate and control the activity of a translation initiation factor and influence the biosynthesis of protein; by regulating the expression of genes related to nitrogen metabolism, the protein metabolism is influenced. In addition, L-lysine hydrochloride can participate in energy metabolism in vivo, and can be decomposed into glucose or ketone body to provide energy when carbohydrate is lacked in vivo.
Glutamine can be used as a nutrition supplement and a flavor blending supplement in solid beverages, can supplement glutamine, can improve the oxidation resistance of organisms by keeping and increasing the storage of GSH in tissue cells, stabilize cell membranes and protein structures, protect the functions of important organs such as liver, lung, intestinal tract and immunocytes, maintain the normal functions of kidney, pancreas, gall bladder and liver, and timely and properly supplement glutamine, and can effectively prevent muscle protein decomposition.
By adding the KAT7 gene inhibitor and compounding with L-lysine hydrochloride and L-glutamine, the cell activity of human body can be recovered rapidly, and the effects of aging resistance and oxidation resistance can be achieved.
Further preferably, the solid beverage comprises the following components in parts by weight: 280 parts of human body aging KAT7 gene inhibitor, 20 parts of bovine colostrum, 20 parts of L-lysine hydrochloride, 50 parts of L-glutamine, 125 parts of magnesium malate, 1 part of vitamin C, 175 parts of calcium citrate, 30 parts of trehalose, 0.015 part of edible essence and 0.03 part of stevioside.
By adopting the technical scheme, the raw material components are in the optimal proportion, and the solid beverage obtained by the raw material components and the proportion has the optimal anti-aging and anti-oxidation effects and the highest quality.
Further preferably, the edible essence is a mixture consisting of Uygur powder essence, blueberry essence and powdered fresh milk essence, and the weight ratio of the Uygur powder essence to the blueberry essence to the powdered fresh milk essence is (2-8):2: 1.
By adopting the technical scheme, the powder essence with the taste of you Ge and the blueberry essence and the fresh milk essence are compounded to prepare the composite essence with unique taste, so that the blueberry essence has the advantages of thick and rich sour milk taste, thick and pure blueberry fragrance, lasting fragrance, greenness and health, and capability of comprehensively improving the taste of the solid beverage.
In a second aspect, the application provides a solid beverage of an inhibitor of human body aging KAT7 gene and a preparation method thereof, which adopts the following technical scheme:
a preparation method of a solid beverage of an inhibitor of KAT7 gene for human aging comprises the following steps: (1) sieving; (2) weighing; (3) premixing; (4) mixing; (5) subpackaging and filling; (6) and (6) packaging and warehousing.
By adopting the technical scheme, the operation is simple, the production efficiency is high, more complex equipment is not needed, the large-scale production is suitable, the conditions such as heating and pressurizing are not involved in the production process, and the preparation efficiency is high.
More preferably, in the step (1), the sieving is performed by using a 20-40 mesh sieve.
By adopting the technical scheme, the particle size of the raw materials is controlled to be proper by passing the raw materials through a 20-40-mesh sieve, so that the raw materials are more easily and uniformly mixed during mixing, and the brewing property is better during brewing.
More preferably, the step (3) is specifically configured as follows: mixing human aging KAT7 gene inhibitor, bovine colostrum, L-lysine hydrochloride, L-glutamine and vitamin C for 5-10min to obtain premix.
By adopting the technical scheme, the inhibitor, the amino acid and the vitamin are mixed to prepare the premix before mixing, and then the premix is mixed with the rest auxiliary materials, carriers and the like to prepare the solid beverage with uniformly distributed components and better reconstitution property.
More preferably, the step (4) is specifically configured as follows: mixing the premix with magnesium malate, calcium citrate, trehalose, edible essence and stevioside for 10-15 min.
By adopting the technical scheme, only a simple stirring and mixing mode is adopted, so that the raw material components are uniformly dispersed, the prepared solid beverage has good dissolving property, and the prepared product has good instant property and mouthfeel and is easier to absorb by intestinal tracts.
In summary, the present application has the following beneficial effects:
(1) according to the application, the yeast extract, the green tea extract and the grape skin extract freeze-dried powder are compounded and added into the solid beverage according to the weight ratio of 35-45%, so that the solid beverage can have anti-aging and anti-oxidation effects;
(2) the application also provides a formula of the solid beverage, which can quickly recover cell and body vitality after being eaten by a human body and can achieve the effects of resisting aging and oxidation;
(3) the application provides a preparation method of solid beverage, which does not involve conditions with higher requirements such as heating and the like, is simple, has high efficiency and is suitable for industrial large-scale production.
Detailed Description
The present application will be described in further detail with reference to examples.
Some of the raw material sources in the examples and comparative examples of the present application are shown in table 1 below:
TABLE 1 sources of the raw Material Components
| Raw material components | Source |
| Pichia pastoris extract | Jinan Sheng and chemical Co Ltd |
| Green tea extract | Anhuitong bioengineering Co Ltd |
| L-lysine hydrochloride | Hebei Runsheng Biotech Co., Ltd |
| L-Glutamine | "Hebei PengyishenTech Co Ltd |
| Uygel flavor powder essence | TIANJIN YUCHANG TECHNOLOGY DEVELOPMENT Co.,Ltd. |
| Powdered fresh milk extract | TIANJIN YUCHANG TECHNOLOGY DEVELOPMENT Co.,Ltd. |
Wherein the grape skin immersion liquid freeze-dried powder is obtained by adopting a conventional alcohol extraction method, and the extraction conditions are as follows: the extraction temperature is 30 ℃, the extraction time is 45min, the volume concentration of ethanol is 30 percent, and the pH value is 6.5.
Examples
Example 1
A solid beverage of an inhibitor of KAT7 gene for human aging, the components and their corresponding weights are shown in Table 2, and is prepared by the following steps:
(1) sieving: sieving each raw material component by a 20-mesh sieve for later use;
(2) weighing: weighing the raw materials according to the formula dosage in the table 1 in sequence, wherein in the process of weighing, one person weighs the raw materials and one person rechecks the raw materials;
(3) premixing: adding human aging KAT7 gene inhibitor, bovine colostrum, L-lysine hydrochloride, L-glutamine and vitamin C into a mixer, and mixing for 5min to obtain premix, wherein human aging KAT7 is based on the mixture of yeast extract, green tea extract and grape skin extract lyophilized powder.
(4) Mixing: adding magnesium malate, calcium citrate, trehalose, edible essence and stevioside into the premix, and mixing for 10min, wherein the edible essence is a mixture consisting of Uygur powdered essence, blueberry essence and powdered fresh milk essence;
(5) subpackaging and filling: filling the uniformly mixed finished product according to the standard of 8g per bag;
(6) packaging and warehousing: packaging according to requirements, then inspecting the product by a quality department, and warehousing after the product is qualified.
Examples 2 to 6
A solid beverage of an inhibitor of KAT7 gene for aging in human body is different from example 1 in that each component and the corresponding weight are shown in Table 1.
TABLE 2 Components and weights (kg) thereof in examples 1-6
Example 7
A solid drink of an inhibitor of the KAT7 gene for aging in human body, which is different from example 1, is prepared by the following steps:
(1) sieving: sieving each raw material component by a 30-mesh sieve for later use;
(2) weighing: weighing the raw materials according to the formula dosage in the table 1 in sequence, wherein in the process of weighing, one person weighs the raw materials and one person rechecks the raw materials;
(3) premixing: adding human aging KAT7 gene inhibitor, bovine colostrum, L-lysine hydrochloride, L-glutamine and vitamin C into a mixer, and mixing for 5min to obtain premix, wherein human aging KAT7 is based on the mixture of yeast extract, green tea extract and grape skin extract lyophilized powder.
(4) Mixing: adding magnesium malate, calcium citrate, trehalose, edible essence and stevioside into the premix, and mixing for 10min, wherein the edible essence is a mixture consisting of Uygur powdered essence, blueberry essence and powdered fresh milk essence;
(5) subpackaging and filling: filling the uniformly mixed finished product according to the standard of 8g per bag;
(6) packaging and warehousing: packaging according to requirements, then inspecting the product by a quality department, and warehousing after the product is qualified.
Example 8
A solid drink of an inhibitor of the KAT7 gene for aging in human body, which is different from example 1, is prepared by the following steps:
(1) sieving: sieving each raw material component by a 40-mesh sieve for later use;
(2) weighing: weighing the raw materials according to the formula dosage in the table 1 in sequence, wherein in the process of weighing, one person weighs the raw materials and one person rechecks the raw materials;
(3) premixing: adding human aging KAT7 gene inhibitor, bovine colostrum, L-lysine hydrochloride, L-glutamine and vitamin C into a mixer, and mixing for 10min to obtain premix, wherein human aging KAT7 is based on the mixture of yeast extract, green tea extract and grape skin extract lyophilized powder.
(4) Mixing: adding magnesium malate, calcium citrate, trehalose, edible essence and stevioside into the premix, and mixing for 15min, wherein the edible essence is a mixture consisting of Uygur powdered essence, blueberry essence and powdered fresh milk essence;
(5) subpackaging and filling: filling the uniformly mixed finished product according to the standard of 10g per bag;
(6) packaging and warehousing: packaging according to requirements, then inspecting the product by a quality department, and warehousing after the product is qualified.
Comparative example
Comparative example 1
A solid beverage as an inhibitor of KAT7 gene for human aging is different from that of example 1 in that yeast extract is not added to the solid beverage.
Comparative example 2
A solid beverage as an inhibitor of KAT7 gene for aging of human body is different from that of example 1 in that green tea extract is not added to the solid beverage.
Comparative example 3
A solid beverage of an inhibitor of KAT7 gene for human aging is different from the solid beverage of example 1 in that grape skin immersion liquid freeze-dried powder is not added in the solid beverage.
Comparative example 4
A solid beverage of an inhibitor of KAT7 gene for human aging is different from that of example 1 in that yeast extract, green tea extract and lyophilized powder of grape skin soaking solution are not added in the solid beverage.
Performance test
Anti-aging and anti-oxidation experiments were performed on the human aging KAT7 gene inhibitor solid beverages prepared in examples 1-8 and comparative examples 1-4, respectively.
1. Anti-aging experiments:
feeding hermaphrodite nematodes on nematode standard culture medium coated with escherichia coli, and performing inverted culture at 20 ℃. Nematode longevity was measured on day 4 after synchronization, and nematodes of the same size were selected and placed in 14 groups of culture media, each of which contained the solid beverages prepared in examples 1 to 8 and comparative examples 1 to 4, at a concentration of 50 mg/mL. The day of grouping was recorded as nematode life initiation day 0 until nematode life termination as nematode life cycle. The nematodes on the plates were transferred to the same new plate every 24h during the nematode life-span, and the survival rates of the groups were recorded on days 10, 15 and 20, respectively, and the test results are shown in table 3 below.
As can be seen from the test data in Table 3, the survival rates of nematodes were uniformly higher in examples 1 to 8 than in comparative example 4 in the case of 10 days, 15 days and 20 days. The nematode survival rates were improved in comparative examples 1-3 compared to comparative example 4, but the improvement was significantly less than in examples 1-8 compared to comparative example 4. The yeast extract, the green tea extract and the grape skin immersion liquid freeze-dried powder are compounded to be used as an inhibitor, and after the inhibitor is added into the solid beverage, the solid beverage can have a high anti-aging effect.
TABLE 3 test results of antiaging Effect
2. Antioxidant experiment:
160 female mice (provided by Beijing Huafukang Biotechnology Co., Ltd.) aged 8-9 weeks are randomly divided into 16 groups, each group contains 10 mice, common commercial maintenance feed is suitable for feeding for 5 days, D-galactose 500mg/kg & BW is used for intraperitoneal injection to prepare an oxidation model, the injection amount is 0.1mL/10g & BW, the time of the injection is 1 time per day, and the model is continuously modeled for 6 weeks. Namely, 1 blank control group, 1 model control group and 14 experimental groups (each group was separately subjected to gavage with the solid beverage liquid prepared in examples 1 to 8 and comparative examples 1 to 4, the gavage dose was 0.9g/kg, and the gavage was performed 2 times a day), the model control group was given an equal volume of distilled water, and the model control group and each experimental group were continuously given the same dose of D-galactose for 30 days while the test sample was given. The liver was sampled at the end of the experiment, and after 5% homogenate was prepared, the activity of superoxide dismutase (SOD) in liver homogenate was measured according to the requirements of a kit (purchased from Shanghai Zheng Bio-technology Co., Ltd., WST-1 method), and the unit was converted into U/mgprot based on the tissue protein content. The test results are shown in table 4 below.
As can be seen from the test data in table 4, the mouse SOD activity in the model control group was significantly reduced compared to the blank control group, indicating that the model was successfully constructed.
Compared with a model control group, the solid beverage for intragastric administration in the comparative examples 1 to 3 respectively has a certain degree of improved SOD activity because the solid beverage contains the yeast extract, the green tea extract and the grape skin immersion liquid freeze-dried powder, which indicates that the solid beverage added with the yeast extract, the green tea extract and the grape skin immersion liquid freeze-dried powder has a certain antioxidation effect.
Compared with the model control group, the solid beverage for intragastric administration of the mice in the comparative example 4 does not contain the inhibitor, and the SOD activity is not obviously improved.
Compared with the model control group, the solid beverage for intragastric administration of the mice in examples 1-8 contains the inhibitor, and the SOD activity of the mice is obviously improved and greatly improved, which shows that the solid beverage can be endowed with higher antioxidation after the yeast extract, the green tea extract and the grape skin immersion liquid freeze-dried powder are compounded to be used as the inhibitor and added into the solid beverage.
TABLE 4 antioxidant Effect test results
The above description is only a preferred embodiment of the present application, and the protection scope of the present application is not limited to the above embodiments, and all technical solutions belonging to the idea of the present application belong to the protection scope of the present application. It should be noted that several improvements and modifications to the present application without departing from the principles of the present application will occur to those skilled in the art, and such improvements and modifications should also be considered within the scope of the present application.
Claims (10)
1. The solid beverage is characterized by comprising 35-45 wt% of human aging KAT7 gene inhibitor, wherein the human aging KAT7 gene inhibitor is a mixture of yeast extract, green tea extract and grape skin extract freeze-dried powder, and the weight ratio of the yeast extract, the green tea extract and the grape skin extract freeze-dried powder is 1 (3-5) to 2-4.
2. The solid beverage of inhibitor of human aging KAT7 gene as claimed in claim 1, wherein the weight ratio of the yeast extract, green tea extract and grape skin extract lyophilized powder is 1:4: 3.
3. The solid beverage of inhibitor of human aging KAT7 gene of claim 1, wherein the yeast extract is pichia pastoris extract.
4. The solid beverage of inhibitor of human body aging KAT7 gene as claimed in claim 1, which comprises the following components in parts by weight: 350 parts of human body senescence KAT7 gene inhibitor 210-containing material, 10-30 parts of bovine colostrum, 15-25 parts of L-lysine hydrochloride, 40-60 parts of L-glutamine, 150 parts of magnesium malate 100-containing material, 0.5-1.5 parts of vitamin C, 200 parts of calcium citrate-containing material, 10-50 parts of trehalose, 0.01-0.02 part of edible essence and 0.01-0.05 part of stevioside.
5. The solid beverage of inhibitor of human body aging KAT7 gene as claimed in claim 4, which comprises the following components in parts by weight: 280 parts of human body aging KAT7 gene inhibitor, 20 parts of bovine colostrum, 20 parts of L-lysine hydrochloride, 50 parts of L-glutamine, 125 parts of magnesium malate, 1 part of vitamin C, 175 parts of calcium citrate, 30 parts of trehalose, 0.015 part of edible essence and 0.03 part of stevioside.
6. The human aging KAT7 gene inhibitor solid beverage as claimed in claim 4, wherein the flavoring essence is a mixture of Uygur powdered essence, blueberry essence and powdered fresh milk essence, and the weight ratio of the Uygur powdered essence, blueberry essence and powdered fresh milk essence is (2-8):2: 1.
7. The method for preparing the solid beverage of inhibitor of human body aging KAT7 gene as claimed in any one of claims 1 to 6, comprising the steps of: (1) sieving; (2) weighing; (3) premixing; (4) mixing; (5) subpackaging and filling; (6) and (6) packaging and warehousing.
8. The method according to claim 7, wherein the sieving in the step (1) is performed by using a 20-40 mesh sieve.
9. The preparation method according to claim 7, wherein the step (3) is specifically configured as follows: mixing human aging KAT7 gene inhibitor, bovine colostrum, L-lysine hydrochloride, L-glutamine and vitamin C for 5-10min to obtain premix.
10. The preparation method according to claim 9, wherein the step (4) is specifically configured as follows: mixing the premix with magnesium malate, calcium citrate, trehalose, edible essence and stevioside for 10-15 min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110423994.8A CN112998101A (en) | 2021-04-20 | 2021-04-20 | Solid beverage of inhibitor of KAT7 gene for human body aging and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110423994.8A CN112998101A (en) | 2021-04-20 | 2021-04-20 | Solid beverage of inhibitor of KAT7 gene for human body aging and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112998101A true CN112998101A (en) | 2021-06-22 |
Family
ID=76388738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110423994.8A Pending CN112998101A (en) | 2021-04-20 | 2021-04-20 | Solid beverage of inhibitor of KAT7 gene for human body aging and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112998101A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113854462A (en) * | 2021-10-22 | 2021-12-31 | 上海舒泽生物科技研究所 | Solid beverage containing human body aging BAZ2B gene inhibitor and preparation method thereof |
| CN113951414A (en) * | 2021-10-22 | 2022-01-21 | 上海舒泽生物科技研究所 | Yeast fermented solid beverage containing GLS1 inhibitor and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070232528A1 (en) * | 2004-04-30 | 2007-10-04 | Hanshermann Franke | Formulation comprising histone deacetylase inhibitors |
| CN101632655A (en) * | 2009-08-04 | 2010-01-27 | 南京大渊美容保健有限公司 | Resveratrol and bioflavonoid nutritional composition for delaying senility |
| CN103704720A (en) * | 2013-12-20 | 2014-04-09 | 林元藻 | Anti-aging healthcare food for middle aged and elderly people |
| US20170174644A1 (en) * | 2014-04-03 | 2017-06-22 | Cambridge Enterprise Limited | Nat10 modulators for treating or preventing laminopathies, aging and cancer |
| CN109662231A (en) * | 2019-01-09 | 2019-04-23 | 西安源森生物科技有限公司 | A kind of solid beverage and preparation method thereof with anti-oxidation efficacy |
| CN111642668A (en) * | 2020-06-29 | 2020-09-11 | 上海圣岳生物科技有限公司 | Solid beverage containing beta-nicotinamide mononucleotide and preparation method thereof |
| CN111758867A (en) * | 2020-06-29 | 2020-10-13 | 上海圣岳生物科技有限公司 | Solid beverage containing recombinant human auxin microcapsules and preparation method thereof |
| CN112138162A (en) * | 2020-09-29 | 2020-12-29 | 中国科学院动物研究所 | Application of substance for reducing KAT7 content or activity in preventing aging and treating hepatic fibrosis |
-
2021
- 2021-04-20 CN CN202110423994.8A patent/CN112998101A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070232528A1 (en) * | 2004-04-30 | 2007-10-04 | Hanshermann Franke | Formulation comprising histone deacetylase inhibitors |
| CN101632655A (en) * | 2009-08-04 | 2010-01-27 | 南京大渊美容保健有限公司 | Resveratrol and bioflavonoid nutritional composition for delaying senility |
| CN103704720A (en) * | 2013-12-20 | 2014-04-09 | 林元藻 | Anti-aging healthcare food for middle aged and elderly people |
| US20170174644A1 (en) * | 2014-04-03 | 2017-06-22 | Cambridge Enterprise Limited | Nat10 modulators for treating or preventing laminopathies, aging and cancer |
| CN109662231A (en) * | 2019-01-09 | 2019-04-23 | 西安源森生物科技有限公司 | A kind of solid beverage and preparation method thereof with anti-oxidation efficacy |
| CN111642668A (en) * | 2020-06-29 | 2020-09-11 | 上海圣岳生物科技有限公司 | Solid beverage containing beta-nicotinamide mononucleotide and preparation method thereof |
| CN111758867A (en) * | 2020-06-29 | 2020-10-13 | 上海圣岳生物科技有限公司 | Solid beverage containing recombinant human auxin microcapsules and preparation method thereof |
| CN112138162A (en) * | 2020-09-29 | 2020-12-29 | 中国科学院动物研究所 | Application of substance for reducing KAT7 content or activity in preventing aging and treating hepatic fibrosis |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113854462A (en) * | 2021-10-22 | 2021-12-31 | 上海舒泽生物科技研究所 | Solid beverage containing human body aging BAZ2B gene inhibitor and preparation method thereof |
| CN113951414A (en) * | 2021-10-22 | 2022-01-21 | 上海舒泽生物科技研究所 | Yeast fermented solid beverage containing GLS1 inhibitor and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112998101A (en) | Solid beverage of inhibitor of KAT7 gene for human body aging and preparation method thereof | |
| EP2596703B1 (en) | Yeast extract containing lactic acid | |
| CN106103696B (en) | Novel lactobacillus paracasei strain | |
| AU2007252785A1 (en) | Guava leaf extract powder and method for production thereof | |
| CN110699219B (en) | A compound wine containing gamma-aminobutyric acid and hyaluronic acid or its salt, and its preparation method | |
| JP2005312438A (en) | FOOD MATERIAL WITH HIGH gamma-AMINOBUTYRIC ACID CONTENT AND METHOD FOR PRODUCING THE SAME | |
| CN113854461A (en) | Composite post-vitality solid beverage and preparation method thereof | |
| Zhang et al. | New technology to overcome defects in production of fermented plant products-a review | |
| CN103006586B (en) | Epirubicin hydrochloride lyophilized injectable powder and preparation method thereof | |
| CN111066991A (en) | Preparation method of composite prebiotics solid beverage for improving gastrointestinal tract function | |
| CN113208077A (en) | Preparation method of probiotic medlar vinegar jelly | |
| CN111642668A (en) | Solid beverage containing beta-nicotinamide mononucleotide and preparation method thereof | |
| JP5571650B2 (en) | Drugs for non-alcoholic fatty liver disease and / or non-alcoholic steatohepatitis | |
| KR20220034453A (en) | Preparation method of ingredients powder fermented by lactic acid bacteria | |
| CN109452607B (en) | Sauce containing enzymatic extract of abalone and its preparation method | |
| CN114588248B (en) | Composition for preventing and treating alcohol cancer and preparation method thereof | |
| KR101429665B1 (en) | Preparation Method of Fermented Products containing ginsenoside and GABA by fermentation technology with lactic acid bacteria from red ginseng and seaweeds | |
| KR20120040458A (en) | Pear jam composition comprising fermented materials using lactic acid bacteria, and the preparation method thereof | |
| JP2006182654A (en) | Body fat accumulation suppressing or reducing agent | |
| KR20190061527A (en) | Composition comprising fermentation product using mushroom for anti-obesity and process for the preparation thereof | |
| CN113017047A (en) | Preparation method of pickled vegetables | |
| CN112457944A (en) | Production process of ginger and garlic aromatic vinegar capable of promoting digestion, relieving exterior syndrome and harmonizing stomach | |
| JP2006265142A (en) | Body fat accumulation inhibiting or decreasing agent | |
| JP4468831B2 (en) | Fermented acerola product containing a large amount of γ-aminobutyric acid and method for producing the same | |
| CN114752527B (en) | Strain 11-3 and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |